Yoh M, Frimpong E K, Voravuthikunchai S P, Honda T
Research Center for Emerging Infectious Diseases, Osaka University, Japan.
Can J Microbiol. 1999 Sep;45(9):732-9.
In Japan, antimicrobial agent therapy for patients with diarrhea due to enterovirulent organisms including enterohemorrhagic Escherichia coli (EHEC) is common, and norfloxacin (NFLX), fosfomycin, and kanamycin are recommended for EHEC treatment by the Japanese Ministry of Health and Welfare. The aim of this study was to analyze the effects of antimicrobial agents which have been used or recommended for the treatment of EHEC on the production of verotoxin (VT) in vitro. Subinhibitory concentrations of quinolones, NFLX, sparofloxacin (SPFX), and grepafloxacin (GPFX) markedly stimulated the productions of VT1 and VT2. The macrolide azithromycin (AZM), erythromycin (EM), and clarithromycin (CAM) did not stimulate the production of VT at a wide range of concentrations. These in vitro results indicate that when quinolones are prescribed for a patient infected with EHEC, the concentration of antimicrobial agents used in vivo and the susceptibility of the EHEC strains against quinolones should be taken into consideration.
在日本,对包括肠出血性大肠杆菌(EHEC)在内的肠道致病微生物引起的腹泻患者进行抗菌药物治疗很常见,日本厚生省推荐使用诺氟沙星(NFLX)、磷霉素和卡那霉素治疗EHEC。本研究的目的是分析已用于或推荐用于治疗EHEC的抗菌药物对体外vero毒素(VT)产生的影响。喹诺酮类药物、NFLX、司帕沙星(SPFX)和格帕沙星(GPFX)的亚抑菌浓度显著刺激VT1和VT2的产生。大环内酯类阿奇霉素(AZM)、红霉素(EM)和克拉霉素(CAM)在很宽的浓度范围内均未刺激VT的产生。这些体外研究结果表明,当给感染EHEC的患者使用喹诺酮类药物时,应考虑体内使用的抗菌药物浓度以及EHEC菌株对喹诺酮类药物的敏感性。